These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16205767)

  • 21. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
    D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
    Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant endocrine therapy in breast cancer.
    Beresford MJ; Ravichandran D; Makris A
    Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Hrushesky WJ; Retsky M; Baum M; Demicheli R
    J Natl Cancer Inst; 2007 Jul; 99(13):1053; author reply 1053-4. PubMed ID: 17596578
    [No Abstract]   [Full Text] [Related]  

  • 25. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
    Manikhas AG; Skvortsov VA; Manikhas GM; Raskin GA; Oganesian AS; Shemerovskiĭ AK
    Vopr Onkol; 2011; 57(5):641-4. PubMed ID: 22238936
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer.
    da Silva BB; Pires CG; dos Santos AR; de Castro-Leão AH; Alencar AP; Lopes-Costa PV
    Gynecol Obstet Invest; 2009; 67(2):103-8. PubMed ID: 18953168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
    Akashi-Tanaka S; Omatsu M; Shimizu C; Ando M; Terada K; Shien T; Kinoshita T; Fujiwara Y; Seki K; Hasegawa T; Fukutomi T
    Breast; 2007 Oct; 16(5):482-8. PubMed ID: 17418576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study.
    Hartley MC; McKinley BP; Rogers EA; Kalbaugh CA; Messich HS; Blackhurst DW; Lokey JS; Trocha SD
    Am Surg; 2006 Dec; 72(12):1189-94; discussion 1194-5. PubMed ID: 17216817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant endocrine therapy for locally advanced breast cancer.
    Ma CX; Ellis MJ
    Semin Oncol; 2006 Dec; 33(6):650-6. PubMed ID: 17145344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inappropriate ATAC on tamoxifen.
    Ucci G
    Lancet Oncol; 2008 Apr; 9(4):314-5. PubMed ID: 18374286
    [No Abstract]   [Full Text] [Related]  

  • 38. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
    Peppercorn J; A Carey L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
    Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
    Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.